Edition:
United States

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

1.16USD
22 Jun 2018
Change (% chg)

$0.04 (+3.57%)
Prev Close
$1.12
Open
$1.16
Day's High
$1.16
Day's Low
$1.11
Volume
55,541
Avg. Vol
47,703
52-wk High
$8.95
52-wk Low
$1.04

Select another date:

Wed, Jun 13 2018

Flex Pharma to scrap two mid-stage neuromuscular disease trials

U.S. drug developer Flex Pharma Inc said on Wednesday it plans to stop two ongoing mid-stage trials, testing its lead drug to treat neuromuscular diseases, following safety concerns.

UPDATE 1-Flex Pharma to scrap two mid-stage neuromuscular disease trials

June 13 U.S. drug developer Flex Pharma Inc said on Wednesday it plans to stop two ongoing mid-stage trials, testing its lead drug to treat neuromuscular diseases, following safety concerns.

Flex Pharma to cut 60 percent of workforce

June 13 U.S. drug developer Flex Pharma Inc said on Wednesday it plans to reduce its workforce by 60 percent, as part of a restructuring, and was ending certain ongoing mid-stage trials.

BRIEF-Flex Pharma Reports Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $-0.49 -- THOMSON REUTERS I/B/E/S

BRIEF-Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis

* FLEX PHARMA REPORTS POSITIVE TOPLINE DATA FROM EXPLORATORY PHASE 2 TRIAL OF FLX-787 IN MULTIPLE SCLEROSIS

BRIEF-Flex Pharma Reports Q4 Loss Per Share $0.46

* EXPECTS TO HAVE SUFFICIENT CAPITAL TO FUND ITS OPERATIONS TO MID 2019 Source text for Eikon: Further company coverage:

BRIEF-Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business‍​

* FLEX PHARMA - ENGAGED INVESTMENT BANKING FIRM TO ASSIST WITH CONSIDERATION OF STRATEGIC ALTERNATIVES FOR CO'S HOTSHOT CONSUMER PRODUCT BUSINESS‍​ Source text: (http://bit.ly/2F0i8Tu) Further company coverage:

Select another date: